CTIS2023-503799-25-00招募中1 期
IMIMFCTL/TRAM/1
Parc De Salut Mar0 个研究点目标入组 25 人开始时间: 2023年2月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Physiologically based pharmacokinetic modelling of oral and intranasal formulations of zolmitriptan in healthy volunteershealthyCTIS2023-504492-24-00Parc De Salut Mar8
进行中（未招募）
1 期
A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy ParticipantsInflammatory diseaseMedDRA version: 20.0Level: LLTClassification code: 10021426Term: Immune system disorder (NOS) Class: 10021428CTIS2023-503917-31-00Immunorx Pharma Inc.81
进行中（未招募）
不适用
Administration of a single dose or of three doses of AM-101to patients with Tinnitus (Ringing in the Ears) and comparision of both doses.Acute inner ear tinnitus following acute acustic trauma, acute otitis media, middle ear surgery, or inner ear barotraumaMedDRA version: 14.1Level: PTClassification code 10043882Term: TinnitusSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2011-005384-24-DEAuris Medical AG72
进行中（未招募）
1 期
Administration of a single dose or of three doses of AM-101to patients with Tinnitus (Ringing in the Ears) and comparision of both doses.Acute inner ear tinnitus following acute acustic trauma, acute otitis media, middle ear surgery, or inner ear barotraumaMedDRA version: 14.1Level: PTClassification code 10043882Term: TinnitusSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2011-005384-24-BEAuris Medical AG72
招募中
1 期
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial)Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-506854-19-00Immatics Biotechnologies GmbH50